HeLa nuclear extract (Anisomycin treated)
Catalog No: 36111 | Format: 200 µg | ¥2,860 | Buy |
Contents
2 x 100 µg of HeLa nuclear extract (Anisomycin treated) at 2.5 µg/µl.
Background
HeLa nuclear extract (Anisomycin treated) was prepared from a cell culture of the HeLa human epithelial carcinoma cell line that was treated with anisomycin, an antibiotic and protein synthesis inhibitor. Anisomycin is also a potent inhibitor of the p38/JNK MAPK pathway.
The HeLa cell line was originally derived from cells obtained in 1951 from Henrietta Lacks, a cervical cancer patient who eventually died from her cancer. The HeLa cell line is one of the oldest and most commonly utilized immortal cell lines in scientific research. These cells are highly prolific and easily sustainable, allowing for flexibility in their application in various fields of scientific research, including cancer biology, virology, and human disease. To date, over 60,000 publications across various disciplines have referenced the use of HeLa cells.
Application Notes
HeLa nuclear extract (Anisomycin treated) is specifically recommended for analysis of protein synthesis and the p38/JNK MAPK pathway.
Extract Origin
Human Cervix Adenocarcinoma
Extract Composition
HeLa nuclear extract is supplied in Dilution Buffer (20 mM Hepes pH 7.5, 400 mM NaCl, 20% glycerol, 0.1 mM EDTA, 10 mM NaF, 10 µM Na2MoO4, 1 mM NaVO3, 10 mM PNPP, 10 mM β-glycerophosphate, 1 mM DTT and protease inhibitors). Cells were cultured in medium supplemented with 5 µM Anisomycin for 1 hour at 37°C immediately prior to harvesting.
Quality Control
Each lot has been tested for ATF-2 activation by using TransAM® Kits.
Storage
To ensure stability, extracts should be stored at -80°C.
We recommend aliquoting the extracts into single-use fractions and then storing them at -80°C. This eliminates repeated freeze/thaw cycles.
Guarantee
This product is guaranteed for 6 months from date of receipt.
This product is for research use only and is not for use in diagnostic procedures.